Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

2.830 +0.120 (+4.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,973
Open 2.720
Bid (Size) 2.740 (15)
Ask (Size) 2.900 (6)
Prev. Close 2.710
Today's Range 2.720 - 2.890
52wk Range 2.670 - 14.30
Shares Outstanding 20,300,419
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Syros Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga
Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday
Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in... 
Via Benzinga

Performance

YTD
-20.06%
-20.06%
1 Month
-29.78%
-29.78%
3 Month
-6.60%
-6.60%
6 Month
-54.28%
-54.28%
1 Year
-74.27%
-74.27%

More News

Read More
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Syros to Participate in Upcoming Investor Conferences in March
From Syros Pharmaceuticals
Via Business Wire
Analyst Expectations for Syros Pharmaceuticals's Future
Via Benzinga
Syros Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
From Syros Pharmaceuticals, Inc.
Via Business Wire
Syros Announces Clinical Updates and 2023 Strategic Priorities
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
From Syros Pharmaceuticals
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For November 14, 2022
Via Benzinga
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.